IGF1R and non-small cell lung carcinoma: These findings demonstrate the benefit of inhibiting IGF-IR/IR signaling in a pre-clinical setting and suggest inhibiting IGF-IR/IR signaling should be further evaluated as a potential therapeutic strategy for the treatment of NSCLC.